Novozymes A S – ADR (NASDAQ:NVZMY) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 7, 2016
Zacks Investment Research has downgraded Novozymes A S – ADR (NASDAQ:NVZMY) to Sell in a statement released on Friday October 07, 2016.
Having a price of $43.99, Novozymes A S – ADR (NASDAQ:NVZMY) traded -0.02% lower on the day. With the last stock price down -4.43% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. NVZMY has recorded a 50-day average of $43.63 and a two hundred day average of $46.07. Trade Volume was down over the average, with 310 shares of NVZMY changing hands under the typical 21,042
Recent Performance Chart
Novozymes A S – ADR has PE ratio of 30.64 with a one year low of $37.98 and a one year high of $49.55 and has a market capitalization of $0.
General Company Details For Novozymes A S – ADR (NASDAQ:NVZMY)
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. In June 2013, the Company restructured its sales areas within those segments. The Household Care (old Household Care Enzymes) area comprises cleaning solutions, laundry, dishwashing and microorganism sales for cleaning solutions. The Food & Beverages (old Food & Beverages Enzymes) manufactures enzymes for the food industry. The Bioenergy (old Bioenergy Enzymes) provides enzymes to the energy industry. The Agriculture & Feed area combines old Feed & Other Technical Enzymes area (enzymes sales to the feed industry) and microorganism sales for aquaculture and agriculture. The Technical & Pharma area combines old Feed & Other Technical Enzymes area (enzymes to other technical industries), microorganism sales for wastewater treatment, and Biopharma (recombinant ingredients and technologies).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.